Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
open in screener | publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ATRC AtriCure, Inc. daily Stock Chart
ATRC [NASD]
AtriCure, Inc.
Healthcare | Medical Instruments & Supplies | USA
financial highlights | statements
Index- P/E- EPS (ttm)-0.58 Insider Own3.50% Shs Outstand38.11M Perf Week6.00%
Market Cap1.26B Forward P/E- EPS next Y-0.58 Insider Trans-0.30% Shs Float36.25M Perf Month7.72%
Income-19.10M PEG- EPS next Q-0.17 Inst Own83.70% Short Float4.92% Perf Quarter8.89%
Sales194.80M P/S6.49 EPS this Y24.70% Inst Trans-1.26% Short Ratio8.80 Perf Half Y9.68%
Book/sh4.87 P/B6.82 EPS next Y18.30% ROA-7.50% Target Price36.50 Perf Year98.50%
Cash/sh1.05 P/C31.46 EPS next 5Y20.00% ROE-12.70% 52W Range16.54 - 36.49 Perf YTD8.46%
Dividend- P/FCF- EPS past 5Y-11.30% ROI-12.00% 52W High-9.04% Beta0.27
Dividend %- Quick Ratio2.00 Sales past 5Y20.00% Gross Margin72.50% 52W Low100.67% ATR0.99
Employees570 Current Ratio2.60 Sales Q/Q18.20% Oper. Margin-8.50% RSI (14)66.06 Volatility2.84% 3.25%
OptionableYes Debt/Eq0.32 EPS Q/Q3.20% Profit Margin-10.40% Rel Volume0.76 Prev Close32.94
ShortableYes LT Debt/Eq0.31 EarningsFeb 28 AMC Payout- Avg Volume202.75K Price33.19
Recom- SMA206.44% SMA508.96% SMA20010.96% Volume153,640 Change0.76%
Oct-04-18Reiterated Needham Buy $36 → $39
Aug-02-18Reiterated Stifel Buy $32 → $34
Aug-02-18Reiterated Needham Buy $32 → $36
Jun-18-18Reiterated Needham Buy $26 → $32
Apr-27-18Reiterated Needham Buy $23 → $26
Jan-16-18Reiterated Needham Buy $25 → $23
Nov-02-17Reiterated Needham Buy $26 → $25
Jul-28-17Reiterated Needham Buy $25 → $26
May-30-17Resumed Piper Jaffray Overweight
Jun-30-16Resumed JMP Securities Mkt Outperform
Oct-28-15Reiterated Needham Buy $30 → $23
Oct-06-15Reiterated Needham Buy $32 → $30
Oct-06-15Reiterated Canaccord Genuity Buy $31 → $28
Aug-04-15Reiterated Needham Buy $29 → $32
Jul-29-15Reiterated Needham Buy $26 → $29
Jul-28-15Reiterated Dougherty & Company Buy $25 → $30
Mar-25-15Reiterated Stifel Buy $22 → $25
Mar-25-15Reiterated Canaccord Genuity Buy $26 → $28
Mar-23-15Reiterated Needham Buy $21 → $26
Mar-09-15Initiated Needham Buy $21
Feb-12-19 08:00AM  AtriCure Announces Launch of the cryoICE® cryoSPHERE Probe Business Wire
Feb-05-19 08:00AM  AtriCure Announces the First Patient Enrolled in the ICE-AFIB Clinical Trial Business Wire
Feb-04-19 08:30AM  AtriCure to Announce Fourth Quarter and Full Year 2018 Financial Results Business Wire
Jan-31-19 09:19AM  AtriCure (ATRC) Upgraded to Strong Buy: Here's What You Should Know Zacks
Jan-28-19 07:25AM  Recent Analysis Shows Textron, Occidental Petroleum, AtriCure, Chegg, KBR, and V.F. Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jan-08-19 02:36PM  Who Has Been Buying AtriCure, Inc. (NASDAQ:ATRC) Shares? Simply Wall St.
09:56AM  Here's how Dayton-area stocks performed in 2018 American City Business Journals
Jan-07-19 08:30AM  AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2018 Business Wire
Jan-02-19 02:03PM  These were the best Cincinnati stocks in 2018 American City Business Journals
Dec-27-18 08:47AM  Perrigo Stock Up as Appeal Date for Irish Tax Bill Nears Zacks
Dec-24-18 10:04AM  Perrigo Plunges on $1.9B Tax Bill From Irish Government Zacks
Dec-13-18 08:00AM  AtriCure to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
05:02AM  Hedge Funds Are Crazy About AtriCure Inc. (ATRC) Insider Monkey
Nov-30-18 01:47PM  What Kind Of Shareholders Own AtriCure Inc (NASDAQ:ATRC)? Simply Wall St.
Nov-12-18 08:40AM  Detailed Research: Economic Perspectives on Roku, Exelixis, Scientific Games, Boot Barn, Astronics, and AtriCure What Drives Growth in Today's Competitive Landscape GlobeNewswire -5.56%
Nov-08-18 09:30AM  AtriCure to Present at the Piper Jaffray 30th Annual Healthcare Conference Business Wire
05:20AM  Edited Transcript of ATRC earnings conference call or presentation 1-Nov-18 8:30pm GMT Thomson Reuters StreetEvents
Nov-01-18 06:35PM  AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates Zacks
05:30PM  AtriCure: 3Q Earnings Snapshot Associated Press
04:01PM  AtriCure Reports Third Quarter 2018 Financial Results Business Wire
Oct-22-18 04:01PM  AtriCure to Participate in Upcoming Investor Conferences Business Wire
Oct-16-18 02:12PM  Is AtriCure Inc (NASDAQ:ATRC) A Financially Sound Company? Simply Wall St.
Oct-12-18 09:10AM  Report: Developing Opportunities within Agree Realty, Lattice Semiconductor, American Outdoor Brands, Schneider National, AtriCure, and Universal Display Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-11-18 08:00AM  AtriCure to Announce Third Quarter 2018 Financial Results Business Wire
Oct-10-18 05:20PM  These Cincinnati stocks took the biggest hit amid Dows worst loss since February American City Business Journals -6.15%
Oct-08-18 10:04AM  AtriCure (ATRC) Looks Good: Stock Adds 6.8% in Session Zacks
Oct-05-18 04:29PM  Why Chefs' Warehouse, SMART Global Holdings, and AtriCure Jumped Today Motley Fool +6.76%
08:35AM  The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker Benzinga
Oct-04-18 06:09PM  AtriCure Announces Pricing of Public Offering of Common Stock Business Wire -8.19%
07:59AM  The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut Benzinga
Oct-03-18 04:01PM  AtriCure Reports Preliminary Financial Results for Third Quarter 2018 Business Wire
04:01PM  AtriCure Announces Proposed Public Offering of Common Stock Business Wire
Aug-28-18 08:00AM  AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial Business Wire
Aug-21-18 08:00AM  AtriCure to Present at the Morgan Stanley Global Healthcare Conference Business Wire
Aug-13-18 03:29AM  Edited Transcript of ATRC earnings conference call or presentation 1-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-18 08:25AM  Report: Exploring Fundamental Drivers Behind BancFirst, Materion, Acuity Brands, USA Truck, Marriott International, and AtriCure New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-01-18 06:45PM  AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:38PM  AtriCure: 2Q Earnings Snapshot Associated Press
04:01PM  AtriCure Reports Second Quarter 2018 Financial Results Business Wire
Jul-24-18 04:30PM  ViewRay Appoints Scott Drake as President, Chief Executive Officer and a Member of the Board of Directors, Shar Matin as Chief Operating Officer, and D. Keith Grossman as a Member of the Board of Directors PR Newswire
Jul-20-18 12:50PM  AtriCure Made an Important Upside Breakout TheStreet.com
Jul-16-18 08:00AM  AtriCure to Present at the Canaccord Genuity 38th Annual Growth Conference Business Wire
Jul-11-18 08:00AM  AtriCure to Announce Second Quarter 2018 Financial Results Business Wire
Jul-02-18 05:16AM  The List: Dayton-Area Public Company Executive Compensation American City Business Journals
Jun-15-18 02:44PM  AtriCure stock hits 52-week high American City Business Journals +7.74%
Jun-12-18 08:00AM  AtriCure Announces 2018 Analyst and Investor Meeting Business Wire
Jun-05-18 06:00AM  AtriCure and Baheal Group Establish Partnership and China Distribution Agreement Business Wire
Jun-01-18 08:15AM  The List: Dayton-Area Top 100 Companies American City Business Journals
May-31-18 01:19PM  7 Greater Cincinnati firms among Ohio's 30 top-paying companies: SLIDESHOW American City Business Journals
May-30-18 04:21PM  These are Ohio's 30 top paying companies (Countdown) American City Business Journals
May-08-18 02:40PM  These Cincinnati public companies pay their employees the most: SLIDESHOW American City Business Journals
Apr-27-18 06:03PM  Edited Transcript of ATRC earnings conference call or presentation 26-Apr-18 8:30pm GMT Thomson Reuters StreetEvents +8.54%
12:26PM  Here's why AtriCure stock is surging American City Business Journals
Apr-26-18 06:11PM  AtriCure: 1Q Earnings Snapshot Associated Press
04:05PM  AtriCure Reports First Quarter 2018 Financial Results Business Wire
Apr-10-18 03:19PM  Is There Now An Opportunity In AtriCure Inc (NASDAQ:ATRC)? Simply Wall St.
Apr-09-18 07:30AM  Free Post Earnings Research Report: AtriCures Quarterly Revenues Jumped 11.9%; Net Loss Narrowed ACCESSWIRE
Apr-05-18 08:00AM  AtriCure to Announce First Quarter 2018 Financial Results Business Wire
Mar-15-18 08:00AM  AtriCure to Present at the Needham & Companys 17th Annual Healthcare Conference Business Wire
Mar-09-18 07:40AM  Free Research Report as ConforMIS Reported Better Than Expected Results ACCESSWIRE
Mar-02-18 07:40AM  Report: Developing Opportunities within LCI Industries, Biglari, Graco, Federal Signal, AtriCure, and Perry Ellis International Future Expectations, Projections Moving into 2018 GlobeNewswire
Feb-28-18 09:48PM  AtriCure Inc (ATRC) Files 10-K for the Fiscal Year Ended on December 31, 2017 GuruFocus.com -6.95%
10:11AM  Edited Transcript of ATRC earnings conference call or presentation 26-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
Feb-26-18 05:36PM  AtriCure reports 4Q loss Associated Press
04:05PM  AtriCure Reports Fourth Quarter and Full Year 2017 Financial Results Business Wire
12:00PM  AtriCure, Inc. to Host Earnings Call ACCESSWIRE
11:27AM  AtriCure Q4 Earnings Outlook Benzinga
Feb-22-18 08:00AM  AtriCure Launches the AtriClip® FLEXV Device in the United States Business Wire +5.57%
Feb-20-18 05:01PM  Cincinnati medical device maker gets board refresh American City Business Journals
08:00AM  AtriCure Names Scott Drake Board Chairman Business Wire
Feb-07-18 08:00AM  AtriCure to Announce Fourth Quarter and Full Year 2017 Financial Results Business Wire
Jan-08-18 08:00AM  AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2017 Business Wire
07:35AM  Factors of Influence in 2018, Key Indicators and Opportunity within Insys Therapeutics, LGI Homes, Steelcase, AtriCure, Alliance Holdings GP, and Digital Turbine New Research Emphasizes Economic Growth GlobeNewswire
Dec-14-17 04:05PM  AtriCure to Present at the 36th Annual JP Morgan Healthcare Conference Business Wire
Dec-11-17 01:31PM  ETFs with exposure to AtriCure, Inc. : December 11, 2017 Capital Cube
Dec-01-17 10:26AM  ETFs with exposure to AtriCure, Inc. : December 1, 2017 Capital Cube
Nov-20-17 11:41AM  ETFs with exposure to AtriCure, Inc. : November 20, 2017 Capital Cube
Nov-09-17 04:05PM  AtriCure to Present at the Piper Jaffray 29th Annual Healthcare Conference Business Wire
Nov-08-17 05:37PM  ETFs with exposure to AtriCure, Inc. : November 8, 2017 Capital Cube
Nov-07-17 08:10AM  AtriCure, Inc. :ATRC-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Capital Cube
Nov-02-17 09:05PM  Edited Transcript of ATRC earnings conference call or presentation 1-Nov-17 8:30pm GMT Thomson Reuters StreetEvents -7.77%
Nov-01-17 05:33PM  AtriCure reports 3Q loss Associated Press
04:05PM  AtriCure Reports Third Quarter 2017 Financial Results Business Wire
Oct-26-17 11:01AM  AtriCure, Inc. Value Analysis (NASDAQ:ATRC) : October 26, 2017 Capital Cube
Oct-25-17 08:15AM  AtriCure, Inc. breached its 50 day moving average in a Bearish Manner : ATRC-US : October 25, 2017 Capital Cube
Oct-20-17 08:00AM  AtriCure to Present at the Stifel Healthcare Conference Business Wire
Oct-11-17 11:11AM  Mike Hooven, Founder of AtriCure (NASDAQ: ATRC) and Enable Injections, Joins Genetesis Board of Directors Business Wire
Oct-10-17 08:00AM  AtriCure to Announce Third Quarter 2017 Financial Results Business Wire
Sep-28-17 08:17AM  AtriCure, Inc. breached its 50 day moving average in a Bullish Manner : ATRC-US : September 28, 2017 Capital Cube
Sep-12-17 08:00AM  AtriCure Announces U.S. Launch of the AtriClip® PROV Device Business Wire
Sep-03-17 11:50PM  Edited Transcript of ATRC earnings conference call or presentation 27-Jul-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-18-17 05:00PM  AtriCure to Present at the Morgan Stanley Global Healthcare Conference Business Wire
Aug-15-17 03:22PM  ETFs with exposure to AtriCure, Inc. : August 15, 2017 Capital Cube
09:08AM  AtriCure, Inc. breached its 50 day moving average in a Bullish Manner : ATRC-US : August 15, 2017 Capital Cube
Aug-04-17 07:47AM  Stock surge on Wall Street pushes these 25 S&P 500 stocks to record highs American City Business Journals
Aug-01-17 11:10AM  AtriCure, Inc. :ATRC-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017 Capital Cube
Jul-28-17 09:34AM  AtriCure, Inc. breached its 50 day moving average in a Bearish Manner : ATRC-US : July 28, 2017 Capital Cube +5.07%
Jul-27-17 11:57PM  AtriCure reports 2Q loss Associated Press
04:05PM  AtriCure Reports Second Quarter 2017 Financial Results Business Wire
11:30AM  Investor Network: AtriCure, Inc. to Host Earnings Call ACCESSWIRE
AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wade M. AndrewSVP and CFOJan 28Option Exercise1.501,0001,500181,787Jan 28 04:07 PM
Noznesky Justin JSVP, Mktg & Business DevelopAug 15Sale30.324,000121,280124,920Aug 17 07:54 AM
Collar Mark ADirectorJun 14Sale25.002,09052,25066,898Jun 18 06:28 AM
Noznesky Justin JSVP, Mktg & Business DevelopMay 15Sale23.054,00092,200131,920May 17 04:28 PM
Krell Elizabeth DDirectorMay 08Sale22.8210,000228,20019,967May 09 09:00 AM
Krell Elizabeth DDirectorMay 07Option Exercise9.3010,00093,00029,967May 09 09:00 AM
Krell Elizabeth DDirectorMar 13Sale20.0010,000200,00019,967Mar 14 04:34 PM
Krell Elizabeth DDirectorMar 12Option Exercise14.1710,000141,70029,967Mar 14 04:34 PM
Lanning Mark RDirectorMar 02Option Exercise10.1010,000101,00099,005Mar 02 04:49 PM
GROVES REGINA EDirectorMar 01Buy17.431,00017,43010,469Mar 01 04:03 PM
Drake Scott WilliamDirectorMar 01Buy17.6411,000194,04016,805Mar 02 04:38 PM
open in screener | open in yahoo | open in reuters | open in google
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  
CDXS Codexis, Inc. daily Stock Chart
CDXS [NASD]
Codexis, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-0.89 Insider Own3.50% Shs Outstand54.07M Perf Week1.86%
Market Cap1.19B Forward P/E- EPS next Y-0.14 Insider Trans-29.25% Shs Float51.64M Perf Month33.66%
Income-43.50M PEG- EPS next Q-0.03 Inst Own83.90% Short Float6.63% Perf Quarter42.25%
Sales66.20M P/S17.90 EPS this Y-486.40% Inst Trans3.00% Short Ratio7.29 Perf Half Y51.70%
Book/sh1.02 P/B21.49 EPS next Y39.10% ROA-15.00% Target Price20.08 Perf Year153.41%
Cash/sh1.00 P/C21.87 EPS next 5Y15.00% ROE-25.70% 52W Range8.60 - 23.05 Perf YTD31.26%
Dividend- P/FCF- EPS past 5Y-8.00% ROI-230.40% 52W High-4.90% Beta-0.36
Dividend %- Quick Ratio3.80 Sales past 5Y-10.70% Gross Margin79.20% 52W Low154.88% ATR0.82
Employees116 Current Ratio3.90 Sales Q/Q69.00% Oper. Margin-15.00% RSI (14)70.21 Volatility3.31% 4.36%
OptionableYes Debt/Eq0.00 EPS Q/Q82.50% Profit Margin-14.30% Rel Volume1.00 Prev Close21.79
ShortableYes LT Debt/Eq0.00 EarningsMar 07 AMC Payout- Avg Volume469.57K Price21.92
Recom1.70 SMA2014.32% SMA5018.85% SMA20034.17% Volume469,497 Change0.60%
Jan-17-19Upgrade First Analysis Sec Neutral → Outperform $12 → $19
May-16-18Initiated Stephens Overweight $16
Oct-13-17Reiterated H.C. Wainwright Buy $8 → $8.50
May-31-17Initiated Jefferies Buy $8
Jan-26-17Downgrade First Analysis Sec Overweight → Equal-Weight $5.50
Jan-04-17Upgrade Ladenburg Thalmann Neutral → Buy
Jan-06-16Initiated H.C. Wainwright Buy $6
Feb-14-19 07:00AM  Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria GlobeNewswire
Feb-06-19 07:00AM  Codexis Announces Enzyme Supply Agreement with KYORIN Pharmaceutical for Overactive Bladder Drug Sold in Japan GlobeNewswire
Feb-05-19 04:36PM  A Pact With Merck Sent This Biotech Stock Zooming Near A Breakout Investor's Business Daily +6.09%
03:44PM  Here's Why Codexis Gained as Much as 9.8% Today Motley Fool
07:47AM  The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results Benzinga
Feb-04-19 04:05PM  Codexis Secures Multi-Year Technology Upgrade Package for its CodeEvolver Protein Engineering Platform License with Merck GlobeNewswire
Jan-30-19 06:00PM  3 Top Stocks Under $20 Motley Fool
Jan-14-19 05:04PM  2 Top Small-Cap Stocks to Buy in January Motley Fool
Jan-02-19 10:55AM  Do Institutions Own Codexis, Inc. (NASDAQ:CDXS) Shares? Simply Wall St.
Dec-05-18 06:18PM  Edited Transcript of CDXS earnings conference call or presentation 8-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-28-18 08:45AM  Report: Developing Opportunities within Costco Wholesale, Pepsico, Northern Oil and Gas, Codexis, Sangamo Therapeutics, and BRF S.A. Future Expectations, Projections Moving into 2018 GlobeNewswire +7.18%
Nov-14-18 02:39PM  This Small-Cap Biotech is Quietly Setting the Stage For a Big 2019 Motley Fool
Nov-13-18 12:11PM  Should You Worry About Codexis Incs (NASDAQ:CDXS) CEO Pay? Simply Wall St.
Nov-08-18 07:20PM  Codexis (CDXS) Reports Break-Even Earnings for Q3 Zacks
06:16PM  Codexis: 3Q Earnings Snapshot Associated Press
04:05PM  Codexis Reports Third Quarter 2018 Financial Results GlobeNewswire
07:00AM  Codexis Announces Results of Phase 1a Clinical Trial with CDX-6114 GlobeNewswire
Nov-07-18 04:05PM  Codexis to Present at Two Investment Conferences in November GlobeNewswire +6.34%
Nov-01-18 11:28AM  Will Codexis (CDXS) Report Negative Earnings Next Week? What You Should Know Zacks
07:00AM  Codexis to Hold Third Quarter 2018 Conference Call on November 8 GlobeNewswire
Oct-17-18 07:20AM  Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis Discovering Underlying Factors of Influence GlobeNewswire
Oct-06-18 08:35AM  Better Synthetic Biology Stock: Amyris vs. Codexis Motley Fool
Oct-01-18 07:00AM  Codexis Appoints Claus Ladefoged to Global Enzyme Business Development Role GlobeNewswire
Sep-12-18 04:27PM  Edited Transcript of CDXS earnings conference call or presentation 8-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Sep-11-18 07:11AM  The Zacks Analyst Blog Highlights: AeroVironment, BioSpecifics, Codexis, Avid and American Outdoor Zacks
Sep-10-18 09:23AM  5 Top-Ranked Nasdaq Stocks Defying the Worst September Start Zacks
Sep-05-18 02:33PM  Codexis Inc (NASDAQ:CDXS): Did It Outperform The Industry? Simply Wall St.
Sep-04-18 03:31PM  Here's Why Codexis Gained 19.4% in August Motley Fool
Aug-29-18 07:00AM  Codexis to Present at Three Investment Conferences in September GlobeNewswire
Aug-20-18 08:10AM  Report: Exploring Fundamental Drivers Behind Codexis, Kornit Digital, NewLink Genetics, NCS Multistage, Mountain Province Diamonds, and CSS Industries New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-17-18 12:50PM  4 Under-the-Radar Small Cap Stars Investopedia
Aug-15-18 09:58AM  E-commerce, Favorable Markets Drive Growth at Grainger (GWW) Zacks
Aug-08-18 08:55PM  Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:48PM  Codexis: 2Q Earnings Snapshot Associated Press
04:05PM  Codexis Reports Second Quarter 2018 Financial Results GlobeNewswire
02:30PM  Codexis, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 07:00AM  Codexis to Hold Second Quarter 2018 Conference Call on August 8 GlobeNewswire
Jul-11-18 07:00AM  Codexis Appoints Dr. Hicham Alaoui, Veteran Drug Discoverer, as Vice President, Biotherapeutics Research & Development GlobeNewswire
Jul-09-18 08:00AM  Codexis Doses First Subjects in Phase 1a Trial of CDX-6114 GlobeNewswire
Jul-06-18 07:20AM  Free Technical Research on Clovis Oncology and Three More Biotech Equities ACCESSWIRE
Jun-21-18 08:19AM  3 Growth Stocks I'd Buy Right Now Motley Fool
Jun-16-18 08:46AM  3 Stocks That Could Put Tesla's Returns to Shame Motley Fool
Jun-01-18 08:00AM  New Research Coverage Highlights WPP, Codexis, Natural Resource Partners LP, Mercer International, Booking, and SINOPEC Shangai Petrochemical Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
May-29-18 07:00AM  Codexis to Present at Three Upcoming Investment Conferences GlobeNewswire
May-18-18 04:12AM  Edited Transcript of CDXS earnings conference call or presentation 10-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-11-18 08:11PM  3 High-Growth Stocks That Are Just Getting Started Motley Fool +8.58%
May-10-18 06:40PM  Codexis: 1Q Earnings Snapshot Associated Press
04:05PM  Codexis Reports First Quarter 2018 Financial Results GlobeNewswire
May-03-18 07:00AM  Codexis to Hold First Quarter 2018 Conference Call on May 10 GlobeNewswire
Apr-25-18 07:40AM  Blog Exposure - Codexis Entered into Strategic Collaboration with Porton Pharma Solutions ACCESSWIRE
Apr-23-18 06:00AM  Porton Pharma Solutions and Codexis Launch Global Partnership Business Wire
Apr-09-18 08:10AM  New Research Coverage Highlights Alliance Resource Partners, MyoKardia, Pan American Silver, Stitch Fix, Codexis, and Chemical Financial Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Apr-06-18 11:08AM  Why Codexis, Inc. Stock Is Tumbling Today Motley Fool
Apr-05-18 09:15PM  Codexis Announces Pricing of Public Offering of Common Stock GlobeNewswire
04:02PM  Codexis Announces Proposed Public Offering of Common Stock GlobeNewswire
07:00AM  Codexis to Present at H.C. Wainwright Global Life Sciences Conference in Monte Carlo, Monaco GlobeNewswire
Mar-30-18 03:26PM  Edited Transcript of CDXS earnings conference call or presentation 8-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-25-18 06:35AM  3 Stocks That Feel Like Microsoft in 1986 Motley Fool
Mar-13-18 08:10AM  Detailed Research: Economic Perspectives on GRIDSUM HOLDING, Booking, POSCO, Codexis, Third Point Reinsurance, and Arch Capital Group What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-09-18 03:16PM  Here's Why Codexis Dropped as Much as 14.6% Today Motley Fool
Mar-08-18 06:07PM  Codexis misses Street 4Q forecasts Associated Press
04:05PM  Codexis Reports 2017 Fourth Quarter and Full Year Financial Results GlobeNewswire
12:45PM  Codexis, Inc. to Host Earnings Call ACCESSWIRE
09:32AM  Codexis Q4 Earnings Preview Benzinga
09:23AM  Codexis Inc (NASDAQ:CDXS): Is Breakeven Near? Simply Wall St.
Mar-01-18 07:00AM  Codexis to Hold 2017 Fourth Quarter and Full Year Conference Call on March 8 GlobeNewswire
Feb-23-18 07:56AM  3 Top Small-Cap Stocks to Buy in February Motley Fool
Feb-15-18 07:00AM  Codexis Appoints Molecular Diagnostics Industry Veteran Shawn Clairmont to Lead High-Performance Enzymes Commercialization GlobeNewswire
Feb-12-18 07:00AM  Codexis to Present at the 25th International Molecular Medicine Tri-Conference GlobeNewswire
Jan-22-18 04:08PM  3 Stocks Wall Street Hasn't Heard of Yet Motley Fool
Dec-29-17 11:42AM  ETFs with exposure to Codexis, Inc. : December 29, 2017 Capital Cube
Dec-28-17 08:44AM  Codexis, Inc. :CDXS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 28, 2017 Capital Cube
Dec-24-17 08:37AM  3 Stocks You Can Buy and Hold for the Next Decade Motley Fool
Dec-16-17 08:36AM  3 Top Small-Cap Stocks to Buy in December Motley Fool
Dec-12-17 02:56PM  Codexis, Inc. Value Analysis (NASDAQ:CDXS) : December 12, 2017 Capital Cube +6.94%
Dec-08-17 07:19AM  Codexis, Inc. breached its 50 day moving average in a Bullish Manner : CDXS-US : December 8, 2017 Capital Cube
Dec-01-17 11:48AM  Edited Transcript of CDXS earnings conference call or presentation 9-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-29-17 09:16AM  3 Bioeconomy Stocks That Have a Killer Advantage Motley Fool
Nov-28-17 12:00PM  ETFs with exposure to Codexis, Inc. : November 28, 2017 Capital Cube
Nov-26-17 09:03AM  3 Stocks That Could Put Amazon's Returns to Shame Motley Fool
Nov-13-17 10:45PM  Edited Transcript of CDXS earnings conference call or presentation 9-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-09-17 06:29PM  Codexis reports 3Q loss Associated Press
04:05PM  Codexis Reports Financial Results for the Third Quarter of 2017 GlobeNewswire
12:05PM  Codexis, Inc. to Host Earnings Call ACCESSWIRE
07:00AM  Codexis to Present at Two Investment Conferences in November GlobeNewswire
Nov-06-17 07:21AM  Codexis, Inc. breached its 50 day moving average in a Bullish Manner : CDXS-US : November 6, 2017 Capital Cube
Nov-02-17 11:59AM  ETFs with exposure to Codexis, Inc. : November 2, 2017 Capital Cube
07:00AM  Codexis to Hold 2017 Third Quarter Conference Call on November 9 GlobeNewswire
Oct-25-17 07:48AM  1 Small-Cap Biotech Stock to Buy Right Now Motley Fool
Oct-23-17 10:27AM  ETFs with exposure to Codexis, Inc. : October 23, 2017 Capital Cube
Oct-12-17 10:21AM  ETFs with exposure to Codexis, Inc. : October 12, 2017 Capital Cube +17.16%
08:00AM  Codexis and Nestlé Health Science Enter Into Healthcare-Focused Protein Engineering Platform Partnership GlobeNewswire
Oct-11-17 09:31AM  Codexis, Inc. :CDXS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 11, 2017 Capital Cube
Oct-09-17 12:32PM  3 Hot Stocks Under $10 Investopedia
Oct-04-17 07:45AM  3 Top Small-Cap Stocks to Buy in October Motley Fool
Aug-31-17 07:00AM  Codexis to Present at Four Investment Conferences in September GlobeNewswire
Aug-24-17 02:05PM  Edited Transcript of CDXS earnings conference call or presentation 9-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-16-17 02:07PM  3 Stocks Set to Pop Motley Fool
Aug-09-17 10:14PM  Codexis reports 2Q loss Associated Press
04:05PM  Codexis Reports Financial Results for the Second Quarter of 2017 GlobeNewswire
Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SANGSTER GORDONSVP & Chief Financial OfficerJan 25Option Exercise3.3940,000135,600174,453Jan 28 06:00 PM
SANGSTER GORDONSVP & Chief Financial OfficerJan 25Sale17.1140,000684,236134,453Jan 28 06:00 PM
SANGSTER GORDONSVP & Chief Financial OfficerJan 24Option Exercise3.3935,000118,650169,453Jan 28 06:00 PM
SANGSTER GORDONSVP & Chief Financial OfficerJan 24Sale16.7435,000585,942134,453Jan 28 06:00 PM
BARUCH THOMAS RDirectorDec 28Sale15.9812,500199,725103,093Dec 31 07:14 PM
BARUCH THOMAS RDirectorDec 27Sale16.0912,500201,076115,593Dec 31 07:14 PM
WOLF DENNIS PDirectorDec 26Sale15.839,000142,42586,230Dec 28 08:17 PM
KELLEY BERNARD JDirectorDec 21Sale16.9810,206173,316205,255Dec 26 05:15 PM
Yang Patrick YDirectorDec 20Sale17.8225,000445,49253,817Dec 21 06:39 PM
Yang Patrick YDirectorDec 19Sale19.2225,000480,45878,817Dec 21 06:39 PM
NICOLS JOHN JPresident and CEODec 07Option Exercise3.463,81213,1901,076,491Dec 10 05:36 PM
NICOLS JOHN JPresident and CEODec 07Sale22.093,81284,2091,072,679Dec 10 05:36 PM
NICOLS JOHN JPresident and CEODec 06Option Exercise3.4640,000138,4001,112,679Dec 10 05:36 PM
NICOLS JOHN JPresident and CEODec 06Sale21.7540,000869,8321,072,679Dec 10 05:36 PM
Lalonde JamesSVP, R&DNov 13Sale15.226,726102,395151,317Nov 14 07:11 PM
Lalonde JamesSVP, R&DNov 12Sale15.576,727104,716158,043Nov 14 07:11 PM
SANGSTER GORDONSVP & Chief Financial OfficerOct 03Option Exercise17.1140,000684,516174,453Oct 04 06:36 PM
SANGSTER GORDONSVP & Chief Financial OfficerOct 03Sale17.1140,000684,516134,453Oct 04 06:36 PM
SANGSTER GORDONSVP & Chief Financial OfficerOct 02Option Exercise16.7640,000670,476174,453Oct 04 06:36 PM
SANGSTER GORDONSVP & Chief Financial OfficerOct 02Sale16.7640,000670,476134,453Oct 04 06:36 PM
NICOLS JOHN JPresident and CEOSep 28Option Exercise3.4640,000138,4001,112,679Oct 01 09:52 PM
NICOLS JOHN JPresident and CEOSep 28Sale17.4340,000697,3241,072,679Oct 01 09:52 PM
NICOLS JOHN JPresident and CEOSep 27Option Exercise3.4640,000138,4001,112,679Oct 01 09:52 PM
NICOLS JOHN JPresident and CEOSep 27Sale17.7140,000708,3491,072,679Oct 01 09:52 PM
BARUCH THOMAS RDirectorSep 27Sale18.0712,500225,904128,093Sep 28 07:42 PM
BARUCH THOMAS RDirectorSep 26Sale19.0012,500237,489140,593Sep 28 07:42 PM
WOLF DENNIS PDirectorSep 26Sale19.179,000172,52295,230Sep 28 07:46 PM
Glaub Kathleen SeredaDirectorSep 25Sale18.8314,492272,81663,534Sep 27 05:18 PM
KELLEY BERNARD JDirectorSep 21Sale18.1210,207184,959215,461Sep 25 09:19 PM
Yang Patrick YDirectorSep 19Sale17.9425,000448,428103,817Sep 20 06:30 PM
Glaub Kathleen SeredaDirectorSep 19Sale17.9420,094360,39078,026Sep 20 06:40 PM
Yang Patrick YDirectorSep 18Sale18.4725,000461,750128,817Sep 20 06:30 PM
Lalonde JamesSVP, R&DSep 05Sale17.3512,381214,849164,770Sep 06 05:17 PM
Lalonde JamesSVP, R&DSep 04Sale17.1617,915307,348177,151Sep 06 05:17 PM
KELLEY BERNARD JDirectorAug 30Option Exercise7.4616,666124,328242,334Sep 04 09:03 PM
KELLEY BERNARD JDirectorAug 30Sale17.1516,666285,780225,668Sep 04 09:03 PM
SANGSTER GORDONSVP & Chief Financial OfficerAug 21Sale15.3118,736286,906134,453Aug 23 05:19 PM
WOLF DENNIS PDirectorAug 20Option Exercise10.5118,333192,680122,563Aug 21 06:10 PM
WOLF DENNIS PDirectorAug 20Sale15.2418,333279,404104,230Aug 21 06:10 PM
WOLF DENNIS PDirectorAug 17Option Exercise10.8818,333199,513122,563Aug 21 06:10 PM
WOLF DENNIS PDirectorAug 17Sale14.7118,333269,612104,230Aug 21 06:10 PM
Yang Patrick YDirectorAug 16Sale14.45150,3402,172,4130Aug 20 08:51 PM
NICOLS JOHN JPresident and CEOAug 15Option Exercise3.462,4008,3041,075,079Aug 16 05:28 PM
NICOLS JOHN JPresident and CEOAug 15Sale14.902,40035,7601,072,679Aug 16 05:28 PM
NICOLS JOHN JPresident and CEOAug 14Option Exercise3.4611,85941,0321,084,538Aug 16 05:28 PM
NICOLS JOHN JPresident and CEOAug 14Sale15.1911,859180,1801,072,679Aug 16 05:28 PM
Yang Patrick YDirectorJul 19Sale15.5225,000387,983304,157Jul 20 06:36 PM
Yang Patrick YDirectorJul 18Sale15.4025,000384,920329,157Jul 20 06:36 PM
Glaub Kathleen SeredaDirectorJul 18Sale15.3410,000153,40098,120Jul 20 06:37 PM
Lalonde JamesSVP, R&DJul 17Sale15.277,500114,553195,066Jul 18 06:22 PM
Lalonde JamesSVP, R&DJul 16Sale15.537,500116,457202,566Jul 18 06:22 PM
Dorgan Byron LDirectorJul 16Sale15.4910,000154,880190,593Jul 17 06:37 PM
WOLF DENNIS PDirectorJun 26Sale14.479,000130,210104,230Jun 28 06:59 PM
BARUCH THOMAS RDirectorJun 26Sale14.3812,500179,775153,093Jun 27 06:01 PM
BARUCH THOMAS RDirectorJun 25Sale15.4812,500193,550165,593Jun 27 06:01 PM
KELLEY BERNARD JDirectorJun 21Sale16.5810,206169,255225,668Jun 22 06:43 PM
WOLF DENNIS PDirectorJun 12Sale14.418,947128,967113,230Jun 12 09:00 PM
NICOLS JOHN JPresident and CEOJun 11Option Exercise3.461,8006,2281,074,479Jun 12 07:11 PM
NICOLS JOHN JPresident and CEOJun 11Sale14.481,80026,0551,072,679Jun 12 07:11 PM
NICOLS JOHN JPresident and CEOJun 08Option Exercise3.467,20724,9361,079,886Jun 12 07:11 PM
NICOLS JOHN JPresident and CEOJun 08Sale15.357,207110,6451,072,679Jun 12 07:11 PM
SANGSTER GORDONSVP & Chief Financial OfficerMay 24Sale14.1118,736264,307153,189May 25 05:38 PM
Cheng Pam P.DirectorMay 22Sale14.1719,607277,76558,719May 23 06:04 PM
Cheng Pam P.DirectorMay 21Sale13.8719,608272,01778,326May 23 06:04 PM
Aldridge Michael D.See RemarksMay 17Option Exercise4.3722,00096,14022,000May 18 05:54 PM
Aldridge Michael D.See RemarksMay 17Sale13.5422,000297,8650May 18 05:54 PM
Aldridge Michael D.See RemarksMay 15Option Exercise4.3722,00096,14022,000May 16 08:59 PM
Aldridge Michael D.See RemarksMay 15Sale12.9122,000283,9450May 16 08:59 PM
Lalonde JamesSVP, R&DMay 15Sale12.9010,000129,030210,066May 15 07:06 PM
Lalonde JamesSVP, R&DMay 14Sale13.0910,000130,900220,066May 15 07:06 PM
Smith David VDirectorApr 03Sale10.376,00062,21356,679Apr 05 01:11 PM
BARUCH THOMAS RDirectorMar 29Sale11.0612,500138,195172,170Mar 30 11:56 AM
BARUCH THOMAS RDirectorMar 28Sale11.0512,500138,123184,670Mar 30 11:56 AM
WOLF DENNIS PDirectorMar 27Sale11.1412,500139,300116,254Mar 28 12:27 PM
WOLF DENNIS PDirectorMar 26Option Exercise7.4616,666124,328157,920Mar 28 12:27 PM
WOLF DENNIS PDirectorMar 26Sale11.1529,166325,084128,754Mar 28 12:27 PM
NICOLS JOHN JPresident and CEOMar 23Option Exercise3.4616,15455,8931,088,833Mar 23 08:30 PM
NICOLS JOHN JPresident and CEOMar 23Sale11.4316,154184,6551,072,679Mar 23 08:30 PM
NICOLS JOHN JPresident and CEOMar 22Option Exercise3.466,31121,8361,078,990Mar 23 08:30 PM
NICOLS JOHN JPresident and CEOMar 22Sale11.916,31175,1731,072,679Mar 23 08:30 PM
open in screener | open in yahoo | open in reuters | open in google
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-3.75 Insider Own0.90% Shs Outstand71.82M Perf Week8.27%
Market Cap9.94B Forward P/E- EPS next Y-3.18 Insider Trans-29.19% Shs Float63.00M Perf Month16.09%
Income-245.00M PEG- EPS next Q-1.04 Inst Own96.40% Short Float15.11% Perf Quarter18.57%
Sales273.90M P/S36.30 EPS this Y84.30% Inst Trans3.03% Short Ratio9.40 Perf Half Y10.13%
Book/sh9.66 P/B14.33 EPS next Y28.10% ROA-19.50% Target Price195.32 Perf Year132.42%
Cash/sh11.04 P/C12.54 EPS next 5Y-0.20% ROE-33.70% 52W Range59.13 - 176.50 Perf YTD26.87%
Dividend- P/FCF- EPS past 5Y30.00% ROI-14.20% 52W High-21.56% Beta2.10
Dividend %- Quick Ratio7.80 Sales past 5Y32.90% Gross Margin91.00% 52W Low134.14% ATR5.86
Employees255 Current Ratio8.80 Sales Q/Q70.70% Oper. Margin-83.00% RSI (14)61.41 Volatility3.76% 4.68%
OptionableYes Debt/Eq0.65 EPS Q/Q-48.70% Profit Margin-89.50% Rel Volume0.87 Prev Close134.88
ShortableYes LT Debt/Eq0.65 EarningsFeb 28 AMC Payout- Avg Volume1.01M Price138.45
Recom1.70 SMA207.01% SMA5015.01% SMA20011.88% Volume877,696 Change2.65%
Oct-12-18Initiated Bernstein Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Sep-26-18Reiterated RBC Capital Mkts Outperform $187 → $200
Sep-14-18Resumed BofA/Merrill Buy $199
Sep-06-18Initiated Credit Suisse Outperform $178
Aug-01-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-21-18Reiterated Robert W. Baird Outperform $120 → $202
Jun-20-18Reiterated Needham Buy $109 → $204
Jun-19-18Reiterated H.C. Wainwright Buy $96 → $267
May-18-18Reiterated Goldman Buy $84 → $127
May-11-18Upgrade Barclays Equal Weight → Overweight $55 → $107
May-07-18Reiterated Needham Buy $75 → $109
May-07-18Reiterated H.C. Wainwright Buy $90 → $96
Mar-21-18Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-13-18Reiterated H.C. Wainwright Buy $75 → $92
Jan-22-18Initiated RBC Capital Mkts Outperform
Jan-04-18Initiated Janney Buy $75
Dec-01-17Initiated H.C. Wainwright Buy $75
Oct-06-17Resumed Goldman Buy $71
Oct-02-17Upgrade Morgan Stanley Equal-Weight → Overweight
Feb-15-19 08:56AM  Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review Zacks
Feb-14-19 04:01PM  Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A) GlobeNewswire
08:30AM  Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53 GlobeNewswire
Feb-11-19 11:21AM  Weekly CFO Sells Highlight GuruFocus.com
08:44AM  Implied Volatility Surging for Sarepta (SRPT) Stock Options Zacks
Feb-07-19 08:37PM  What Solid Biosciences' First Failure Means for Sarepta Therapeutics Motley Fool
10:45AM  Solid Biosciences shares drop 70% on disappointing Duchenne data American City Business Journals
09:42AM  Solid Bio Crashes on Gene Therapy Data as Peer Sarepta Gains Bloomberg
Feb-05-19 10:08AM  Weekly CFO Sells Highlight GuruFocus.com
Feb-03-19 02:04PM  3 Gene Therapy Stocks With Huge Catalysts in 2019 Motley Fool
Feb-01-19 12:05PM  Should You Take Comfort From Insider Transactions At Sarepta Therapeutics, Inc. (NASDAQ:SRPT)? Simply Wall St.
09:48AM  6 Biotech Stocks to Watch Now Motley Fool
Jan-31-19 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +7.53%
01:10PM  Fear of Missing Out Is the Main Driving Force in This Market TheStreet.com
09:07AM  Your first trade for Thursday, January 31 CNBC
07:55AM  Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sarepta Therapeutics ACCESSWIRE
Jan-20-19 09:21AM  3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs Motley Fool
Jan-16-19 11:03AM  Here are top analysts' 5 favorite growth stocks for 2019 CNBC
Jan-15-19 04:48PM  Heres your guide to the upcoming biotechnology takeover wave MarketWatch
06:07AM  FDA pilot program could help Wave avoid orphan-drug pitfalls American City Business Journals
Jan-14-19 07:25AM  Analysis: Positioning to Benefit within Alphabet, Globalstar, Ingevity, Vocera Communications, Sarepta Therapeutics, and FLIR Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-12-19 07:31AM  3 Biotech Stocks to Watch in 2019 Motley Fool
Jan-11-19 05:27PM  InvestorPlace Roundup: The Hottest Stocks in the Market Today InvestorPlace
10:59AM  Why Sarepta Therapeutics Stock Is Starting to Shine Again InvestorPlace
Jan-08-19 02:11PM  Janney, Morgan Stanley Say Sarepta's Gene Therapy Remains On Track Benzinga
08:56AM  4 Biotechs That Are Potential Buyouts Post Celgene Deal Zacks
Jan-04-19 11:38AM  Here's Why Sarepta Therapeutics Fell 15.7% in December Motley Fool +8.21%
Jan-03-19 08:50AM  Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply Zacks
Jan-02-19 08:30AM  Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy GlobeNewswire
08:00AM  Sarepta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-31-18 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Dec-24-18 01:13PM  Biotech Buying Spree: Why These 3 Stocks Could Get Deals In 2019 Investor's Business Daily
Dec-21-18 01:36PM  6 Genome Sequencing Stocks to Buy for Big Health-Care Profits Kiplinger
Dec-20-18 08:30AM  Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53 GlobeNewswire
Dec-13-18 08:32AM  Ghost Tree Capitals AUM, Returns and Holdings Insider Monkey
Dec-12-18 11:50AM  Analysts Expect Breakeven For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Simply Wall St.
Dec-11-18 08:30AM  Sarepta Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors GlobeNewswire
Dec-08-18 10:15AM  Is Sarepta Therapeutics Inc (SRPT) A Good Stock To Buy? Insider Monkey
Dec-07-18 08:25AM  New Research Coverage Highlights Callaway Golf, Synchrony Financial, Roper Technologies, Ringcentral, Sarepta Therapeutics, and Advanced Micro Devices Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Dec-06-18 06:50AM  Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and Sarepta Therapeutics ACCESSWIRE
Nov-30-18 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-23-18 09:03AM  Sarepta Stock More Than Doubles This Year So Far: Here's Why Zacks
Nov-16-18 07:00AM  Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Sage Therapeutics ACCESSWIRE
Nov-12-18 04:21PM  These Biopharmas Could Cure Genetic Diseases At $5 Million Apiece Investor's Business Daily
Nov-08-18 07:13PM  Sarepta Therapeutics Announces Pricing of $500,000,000 Public Offering of Common Stock GlobeNewswire -7.68%
Nov-07-18 04:21PM  Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock GlobeNewswire +5.02%
Nov-06-18 10:13AM  Hedge Funds Just Stormed Into This Red-Hot Biotech Company Insider Monkey
08:43AM  Implied Volatility Surging for Sarepta Therapeutics (SPRT) Stock Options Zacks
Nov-05-18 10:17AM  Weekly CEO Buys Highlight GuruFocus.com
Nov-02-18 12:13PM  Weekly CFO Sells Highlight GuruFocus.com
08:30AM  Sarepta Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference GlobeNewswire
Oct-31-18 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +7.50%
08:00AM  Today's Research Reports on Trending Tickers: bluebird bio and Sarepta Therapeutics ACCESSWIRE
Oct-30-18 09:15PM  Sarepta Therapeutics Inc (SRPT) President & CEO Douglas S Ingram Bought $2 million of Shares GuruFocus.com +6.46%
08:00AM  Report: Exploring Fundamental Drivers Behind Sarepta Therapeutics, Reinsurance Group of America, Illinois Tool Works, ATN International, Morningstar, and Hubbell New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-29-18 12:09PM  7 Rising Healthcare Stocks to Consider InvestorPlace
Oct-26-18 08:15AM  Edited Transcript of SRPT earnings conference call or presentation 24-Oct-18 8:30pm GMT Thomson Reuters StreetEvents
Oct-25-18 11:06AM  Sarepta (SRPT) Q3 Earnings & Sales Miss, Exondys 51 Sales Up Zacks
Oct-24-18 07:00PM  Sarepta Therapeutics (SRPT) Reports Q3 Loss, Lags Revenue Estimates Zacks -8.40%
05:53PM  Sarepta Therapeutics: 3Q Earnings Snapshot Associated Press
04:06PM  Sarepta Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Developments GlobeNewswire
08:22AM  Q3 Earnings Preview For Sarepta Therapeutics Benzinga
Oct-23-18 09:31AM  Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT Zacks
Oct-18-18 04:30PM  Sarepta Therapeutics to Announce Third Quarter 2018 Financial Results and Recent Corporate Developments on October 24, 2018 GlobeNewswire
Oct-17-18 11:40AM  Duchenne biotech Sarepta to open gene therapy facility in Ohio American City Business Journals
10:32AM  Sarepta Therapeutics (SRPT) Q3 Earnings Preview: What to Expect Zacks
10:00AM  Sarepta Announces Agreement With Lysogene for Gene Therapy Zacks
Oct-16-18 04:12PM  Boston biopharma commercializing Nationwide Children's gene therapies to add Columbus office, 100 jobs American City Business Journals +5.51%
Oct-15-18 08:00AM  Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Amicus Therapeutics ACCESSWIRE
08:00AM  Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate GlobeNewswire
Oct-12-18 01:46PM  Are Sarepta Therapeutics Incs (NASDAQ:SRPT) Interest Costs Too High? Simply Wall St. +6.96%
Oct-11-18 02:55PM  Sarepta CEO charts path forward on Duchenne drug amid stock slide American City Business Journals
11:11AM  Square Continues to See Extreme Pressure TheStreet.com
10:10AM  Here's Why Sarepta Therapeutics Jumped 17% in September Motley Fool
Oct-08-18 08:30AM  Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Paragon Bioservices, Greatly Enhancing its Commercial Capacity for Future Gene Therapies GlobeNewswire
Oct-05-18 08:30AM  Sarepta Announces Agreement with Nationwide Childrens Hospital for Rights to its Gene Therapy Program to Treat Charcot-Marie-Tooth (CMT) Neuropathy, Globally the Most Common Inherited Neuromuscular Disorder GlobeNewswire -5.47%
Oct-04-18 08:00AM  Today's Research Reports on Trending Tickers: Tesaro and Sarepta Therapeutics ACCESSWIRE
07:59AM  The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut Benzinga
Oct-03-18 05:15PM  Sarepta Therapeutics Announces that at the 23rd International Congress of the World Muscle Society, Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystrophin Trial to Treat Patients with Duchenne Muscular Dystrophy GlobeNewswire
Oct-02-18 01:18PM  Overall Market Breadth Remains Negative TheStreet.com
08:00AM  Today's Research Reports on Trending Tickers: Omeros and Sarepta Therapeutics ACCESSWIRE
Oct-01-18 10:28AM  5 Best Biotech Stocks to Buy In October Zacks -7.89%
Sep-28-18 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-26-18 08:30AM  Sarepta Therapeutics and Jerry R. Mendell, M.D. from Nationwide Childrens Hospital to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program from the 23rd International Annual Congress of the World Muscle Society GlobeNewswire
08:26AM  Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars Zacks
Sep-25-18 10:44AM  FDA Lifts Clinical Hold on Sarepta's DMD Gene Therapy Program Zacks
Sep-24-18 04:43PM  CHMP Reconfirms Negative Opinion for Sarepta's Exondys Zacks
08:19AM  Sarepta stock rises after FDA lifts clinical hold on gene therapy program MarketWatch
07:00AM  Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy Program GlobeNewswire
Sep-21-18 12:01PM  Sarepta investors, analysts shrug off E.U. setback for Duchenne drug American City Business Journals
06:48AM  Sarepta expected, but is disappointed by European regulators decision on DMD treatment MarketWatch
06:30AM  Sarepta Receives Negative CHMP Re-examination Opinion for Eteplirsen GlobeNewswire
Sep-12-18 01:10PM  Corrective Action in This Market Is Often Quite Hidden TheStreet.com +5.07%
Sep-11-18 07:43PM  Why Sarepta Therapeutics, Inc. Stock Jumped 18.8% Higher in August Motley Fool
Sep-10-18 02:17PM  Six Biotechnology Names on My Watch List TheStreet.com
Sep-07-18 05:05PM  Sarepta Therapeutics CEO has a 'big ambition' for muscular dystrophy gene therapy CNBC
03:34PM  Sarepta Therapeutics CEO on soaring stock and drug develo... CNBC Videos
09:30AM  Why Is Sarepta Therapeutics (SRPT) Up 6.4% Since Last Earnings Report? Zacks
09:15AM  Today's Bell Ringer, September 7, 2018 CNBC Videos
08:30AM  Sarepta Therapeutics to Recognize World Duchenne Awareness Day at NASDAQ Opening Bell Ceremony GlobeNewswire
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mahatme SandeshEVP, CFO & CBOFeb 07Option Exercise23.8565,0001,550,25073,649Feb 08 08:02 PM
Mahatme SandeshEVP, CFO & CBOFeb 07Sale145.0065,0009,425,0008,649Feb 08 08:02 PM
Cumbo AlexanderSVP, Chief Commercial OfficerFeb 01Option Exercise22.547,500169,03530,266Feb 01 08:27 PM
Howton David TSVP, General CounselFeb 01Option Exercise21.6521,500465,39149,571Feb 01 08:25 PM
Howton David TSVP, General CounselFeb 01Sale140.0030,0004,200,00019,571Feb 01 08:25 PM
Cumbo AlexanderSVP, Chief Commercial OfficerFeb 01Sale140.0015,0002,100,00015,266Feb 01 08:27 PM
Mahatme SandeshEVP, CFO & CBOJan 31Option Exercise23.8521,198505,57229,847Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 31Sale130.7221,1982,771,0038,649Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 30Option Exercise18.2743,802800,07752,451Feb 01 08:24 PM
Mahatme SandeshEVP, CFO & CBOJan 30Sale130.0043,8025,694,2608,649Feb 01 08:24 PM
Wigzell Hans Lennart RudolfDirectorNov 01Option Exercise8.946,66759,60316,751Nov 02 06:01 PM
Wigzell Hans Lennart RudolfDirectorNov 01Sale140.506,667936,71410,084Nov 02 06:01 PM
BEHRENS M KATHLEENDirectorOct 31Option Exercise3.9610,00039,600126,534Nov 02 06:00 PM
BEHRENS M KATHLEENDirectorOct 31Sale131.7110,0001,317,100116,534Nov 02 06:00 PM
INGRAM DOUGLAS SPresident & CEOOct 30Buy120.3916,6952,009,872415,945Oct 30 07:05 PM
Mahatme SandeshEVP, CFO & CBOOct 24Option Exercise14.8889,4001,330,389128,185Oct 26 06:43 PM
Mahatme SandeshEVP, CFO & CBOOct 24Sale127.74107,52413,735,11620,661Oct 26 06:43 PM
INGRAM DOUGLAS SPresident & CEOAug 15Buy125.2616,0002,004,211399,250Aug 16 07:30 AM
Howton David TSVP, General CounselJul 16Option Exercise13.8550,000692,69172,719Jul 17 06:01 PM
Howton David TSVP, General CounselJul 16Sale136.4650,0006,823,00034,871Jul 17 06:01 PM
Cumbo AlexanderSVP, Chief Commercial OfficerJul 09Option Exercise13.7833,782465,41540,690Jul 11 06:05 PM
Cumbo AlexanderSVP, Chief Commercial OfficerJul 09Sale137.3233,7824,638,94428,766Jul 11 06:05 PM
Barry RichardDirectorJun 27Sale130.3475,0009,775,5003,170,432Jun 29 06:01 PM
Cumbo AlexanderSVP, Chief Commercial OfficerMar 15Option Exercise20.642,50051,60025,767Mar 16 06:10 PM
Mahatme SandeshEVP, CFO & CBOMar 15Option Exercise23.852,50059,62543,395Mar 16 06:08 PM
Howton David TSVP, General CounselMar 15Option Exercise22.152,50055,38231,727Mar 16 06:12 PM
Ruff ShamimSVP, Chief Regulatory AffairsMar 15Option Exercise23.932,50059,81329,465Mar 16 06:13 PM
open in screener | open in yahoo | open in reuters | open in google